How Analysts Feel About MacroGenics, Inc. (MGNX) After Forming Wedge Up?

February 21, 2018 - By Clifton Ray

Investors sentiment decreased to 1.58 in 2017 Q3. Its down 0.15, from 1.73 in 2017Q2. It is negative, as 7 investors sold MacroGenics, Inc. shares while 26 reduced holdings. 11 funds opened positions while 41 raised stakes. 27.72 million shares or 0.96% more from 27.45 million shares in 2017Q2 were reported.
Loring Wolcott Coolidge Fiduciary Advisors Llp Ma reported 213 shares. Parametric Port Associate reported 11,551 shares. Moreover, Swiss Retail Bank has 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 55,200 shares. Tocqueville Asset Mngmt Limited Partnership owns 100,000 shares. Artal Grp reported 200,000 shares stake. Proshare Advsrs Limited Liability Co has 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 23,056 shares. Alliancebernstein Ltd Partnership owns 43,000 shares or 0% of their US portfolio. Tiger Mngmt Ltd Liability Co has 239,667 shares for 0.8% of their portfolio. Emerald Mutual Fund Advisers reported 0.28% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Tower Ltd Liability Corporation (Trc) holds 2,468 shares or 0% of its portfolio. Ameritas Invest Partners Incorporated holds 0% or 2,753 shares. New York-based Renaissance Ltd Liability Company has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Clearbridge Invs Ltd Llc holds 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX) for 3,985 shares. 22,600 were reported by Gam Ag. 161,330 are held by National Bank Of New York Mellon.

Since October 25, 2017, it had 0 buys, and 3 sales for $367,500 activity. Shares for $67,500 were sold by Risser Eric Blasius on Wednesday, January 24.

The stock of MacroGenics, Inc. (MGNX) formed an up wedge with $24.13 target or 4.00 % above today’s $23.20 share price. The 8 months wedge indicates low risk for the $854.29 million company. If the $24.13 price target is reached, the company will be worth $34.17 million more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock decreased 0.43% or $0.1 during the last trading session, reaching $23.2. About 180,999 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has declined 9.76% since February 21, 2017 and is downtrending. It has underperformed by 26.46% the S&P500.

Analysts await MacroGenics, Inc. (NASDAQ:MGNX) to report earnings on February, 27 after the close. They expect $2.58 EPS, up 358.00 % or $3.58 from last year’s $-1 per share. MGNX’s profit will be $95.00M for 2.25 P/E if the $2.58 EPS becomes a reality. After $-1.28 actual EPS reported by MacroGenics, Inc. for the previous quarter, Wall Street now forecasts -301.56 % EPS growth.

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

Among 10 analysts covering MacroGenics (NASDAQ:MGNX), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. MacroGenics had 22 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by Janney Capital given on Thursday, February 18. Morgan Stanley maintained it with “Equal-Weight” rating and $21 target in Monday, August 7 report. The firm has “Buy” rating given on Tuesday, January 23 by SunTrust. SunTrust initiated MacroGenics, Inc. (NASDAQ:MGNX) on Tuesday, December 20 with “Buy” rating. The firm has “Buy” rating given on Wednesday, October 25 by BTIG Research. The stock has “Buy” rating by Zacks on Monday, August 10. Leerink Swann maintained the shares of MGNX in report on Wednesday, October 25 with “Buy” rating. The firm has “Buy” rating given on Monday, October 19 by Citigroup. Morgan Stanley initiated MacroGenics, Inc. (NASDAQ:MGNX) rating on Thursday, February 25. Morgan Stanley has “Equal-Weight” rating and $20 target. Stifel Nicolaus maintained MacroGenics, Inc. (NASDAQ:MGNX) on Monday, September 11 with “Buy” rating.

Another recent and important MacroGenics, Inc. (NASDAQ:MGNX) news was published by which published an article titled: “MacroGenics Announces Date of Fourth Quarter and Full Year 2017 Financial …” on February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: